The Lancet. Infectious diseases
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study.
Josefina L Razzini, Iago Giné-Vázquez, Jing Jin, María-Isolina Santiago-Pérez, Olaia Pérez-Martínez, María-Teresa Otero-Barrós, Nuria Suárez-Gaiche, Rolf Kramer, Leticia Platero-Alonso, Rosa-María Álvarez-Gil, Olga-María Ces-Ozores, Victoria Nartallo-Penas, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Juan-Manuel González-Pérez
Published: 202610.1016/S1473-3099(25)00742-X
Abstract
BACKGROUND: Real-world evidence on nirsevimab impact beyond the first season when given under universal immunisation programmes is emerging. We aimed to assess the medium-term impact of universal infant respiratory syncytial virus (RSV) prophylaxis w…
Preview only. Read the full abstract at the source